Vanguard Global Advisers
LCTX icon

Vanguard Global Advisers’s Lineage Cell Therapeutics LCTX Stock Holding History

Vanguard Global Advisers’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112K Hold
85,795
– – ﹤0.01% 2726
2026
Q1 		$136K Buy
+85,795
New +$145K ﹤0.01% 2600

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Global Advisers's LCTX Position: Q2 2026 in Review

Vanguard Global Advisers held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 85,795 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #2726.

Vanguard Global Advisers first reported a position in LCTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $136K in Q1 2026. 130 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Vanguard Global Advisers held 85,795 shares of Lineage Cell Therapeutics worth $112K as of Q2 2026.
  • Vanguard Global Advisers left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2726 holding.
  • Vanguard Global Advisers first reported a position in Lineage Cell Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Lineage Cell Therapeutics position peaked at $136K in Q1 2026.
  • 130 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.